Date: Monday, November 9, 2015
Session Title: T cell Biology and Targets in Autoimmune Disease Poster I
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled phase IIb study, P140/LupuzorTM had no adverse safety signals and met its primary efficacy end points in lupus patients1. These results confirm data generated in MRL/lpr lupus-prone mice in which the preclinical studies were performed. We found previously that P140 reduces autophagic flux in MRL/lpr B cells2 and that macroautophagy (the best characterized type of autophagy) is abnormally enhanced in T lymphocytes from lupus mice and patients3. More recently, we discovered that in MRL/lpr mice, P140 more precisely targets a selective form of autophagy, chaperone-mediated autophagy. We deciphered the successive steps of P140 action leading in fine to a decay of endogenous antigen processing and loading to MHCII molecules and as a consequence, to a lower activation of autoreactive T cells4. Here, the mechanism of action of P140 was further studied in peripheral cells from normal and lupus individuals.
Methods: Studies were performed ex vivo on B cells from normal donors and lupus patients. A scrambled peptide was used as control. Immunocytochemical analyses were applied to identify the way of P140 enters into B cells. The effect of P140 on MHCII molecules stability was studied using western immunoblotting (WB) and FACS analyses. FACS studies were used to evaluate the effect of P140 on the B cells differentiation into plasmablasts and plasma cells and on BCR signaling amplitude. Microscopy and WB analyses were performed to study the effect of P140 on autophagy.
Results: P140 that is not immunogenic in lupus patients5 showed no direct effect on BCR signaling in normal B cells (mature, transitional, IgG/IgM memory). As in MRL/lpr mice, P140 enters human B cells via a clathrin-dependent endo-lysosomal pathway and induces a decrease of MHCII expression. Higher the SLEDAI score of patients was, higher the P140 effect was measurable. P140 did not induce apoptosis of B cells from healthy or lupus patients. The autophagic flux was affected in P140-treated B cells.
Conclusion: Our findings provide strong arguments to conclude that the mechanism of action of P140 peptide is similar in MRL/lpr mice and lupus patients. These results shed light on mechanisms by which P140/Lupuzor modulates lupus disease in humans affected by this disorder.
Refs: 1Zimmer et al. ARD 2013; 2Page et al. ARD 2011; 3Gros et al. Autophagy 2012; 4Macri et al. Autophagy 2015; 5Schall & Muller Lupus 2015.
To cite this abstract in AMA style:Wilhelm M, Wang F, Schall N, Faludi M, Kleinmann JF, Nashi EP, Martin T, Sibilia J, Pasquali JL, Wallace D, Muller S. Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/autophagy-pathway-as-a-target-of-therapeutic-p140-peptide-used-in-lupus/. Accessed October 22, 2017.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - http://acrabstracts.org/abstract/autophagy-pathway-as-a-target-of-therapeutic-p140-peptide-used-in-lupus/